Fit India Cycling Drive launched by Mandaviya
The Fit India movement took a significant stride towards a healthier and greener India with the launch of ‘Fit India Cycling Drive’ this morning at the Major Dhyan Chand National Stadium here
The National Covid-19 Vaccination Programme has been successfully going on across all states and Union Territories since 16th January, 2021, he added.
Union Minister for Health and Family Welfare and Chemical and Fertilizer Mansukh Mandaviya today released the first commercial batch of COVAXIN from Chiron Behring Vaccines facility of Bharat Biotech in Ankleshwar, Gujarat.
Speaking at the inauguration, Mandaviya said that due to the Prime Minister’s vision, India was able to develop its first indigenous vaccine. He remarked that India is running one of the largest Vaccination programs in the world and it was made possible due to the development of these indigenous vaccines.
Advertisement
The National Covid-19 Vaccination Programme has been successfully going on across all states and Union Territories since 16th January, 2021, he added.
Advertisement
Dedicating the release of the first batch of COVAXIN from Ankleshwar facilities to the Nation, the Union Health Minister said that it is a landmark moment in the journey of India’s fight against COVID-19.
The increase in the production capacity of COVID-19 Vaccines would give further impetus to the pace of Vaccination in India. He added that it is a matter of great pride for us that the research and production of vaccines of two companies Bharat Biotech and Zydus Cadila took place in India.
He also informed that the Ankleshwar plant has a manufacturing capacity of more than 1 crore doses per month starting today.
Talking about India’s contribution to the fight against the global pandemic, he mentioned how India has always been on the forefront of helping other countries in need with essential medicines to deal with COVID situation.
Bharat Biotech is also exploring manufacturing partnerships with its partners in other countries, who have prior expertise with commercial scale manufacturing of inactivated viral vaccines under biosafety containment for further augmentation, he added.
Advertisement